Kwality Pharmaceuticals Ltd has announced the appointment of Mr. Bhavesh Mahajan as Additional Independent Director, effective January 28, 2026. The Board of Directors approved the appointment on the recommendation of the Nomination and Remuneration Committee during their meeting held on January 28, 2026.

Appointment Details

The appointment encompasses specific terms and regulatory compliance requirements as outlined by the company.

Professional Background

Mr. Bhavesh Mahajan brings extensive professional expertise to the Board. He is a Chartered Accountant with over 19 years of experience in audit and assurance, banking audits, direct and indirect taxation, financial consultancy, and corporate advisory services. He serves as Senior Partner of M/s Bhavesh Mahajan & Co., Chartered Accountants, Amritsar, a Category-II CA firm empaneled with the Reserve Bank of India since 2005.

His professional experience includes:

• Statutory audits and internal audits
• Bank and concurrent audits
• GST advisory services
• Forensic accounting
• Financial and strategic planning
• Regulatory compliance management

Qualifications and Certifications

Mr. Mahajan holds membership with the Institute of Chartered Accountants of India (ICAI) and possesses multiple professional certifications including DISA, Forensic Accounting & Fraud Detection, Concurrent Audit of Banks, GST Certification, and Artificial Intelligence for Chartered Accountants.

He has served as empaneled faculty for ICAI covering Ethics, Taxation, and Professional Development programmes. Additionally, he has held leadership positions including Vice Chairman and Secretary of the Amritsar Branch of ICAI.

Regulatory Compliance

Kwality Pharmaceuticals confirmed that Mr. Bhavesh Mahajan satisfies the independence criteria prescribed under the Companies Act, 2013 and SEBI Listing Regulations. The company stated that he is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The appointment disclosure complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Mahajan is not related to any existing Director of the company, ensuring independence in his directorial role. The appointment strengthens the company's governance structure with his extensive financial and regulatory expertise.

Kwality Pharmaceuticals Limited has officially appointed Dr. PreetMohinder Singh Bedi as Additional Independent Director, effective January 1, 2026. The appointment was approved by the Board of Directors during their meeting held on January 1, 2026, following the recommendation of the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI Listing Regulations.

Appointment Details and Regulatory Compliance

Dr. Bedi will serve as Additional Independent Director for a period of five consecutive years, with his tenure running from January 1, 2026, to December 31, 2030. The appointment is subject to approval by the company's shareholders. The company has confirmed that Dr. Bedi satisfies the criteria of independence prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

Professional Background and Qualifications

Dr. PreetMohinder Singh Bedi brings extensive experience to the board, with over 28 years in the pharmaceutical industry. He currently serves as Professor in the Department of Pharmaceutical Sciences and Director of Global Ranking and International Collaboration Cell at Guru Nanak Dev University, Amritsar.

Dr. Bedi has achieved significant recognition in his field, being included in the 2025 Stanford-Elsevier list of the world's top 2% scientists for his lifetime research impact. His academic credentials include B-Pharmacy from Panjab University, Chandigarh, M-Pharmacy from Punjabi University, Patiala, and PhD from Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar.

Research and Academic Achievements

Dr. Bedi's research portfolio demonstrates substantial contributions to pharmaceutical sciences. He has authored over 150 scientific publications and holds patents in Medicinal Chemistry. His research focuses on drug design, synthesis, ADME studies, and biologically active molecules with antimicrobial, antidiabetic, anti-inflammatory, and anticancer activities.

Leadership and Administrative Roles

Dr. Bedi joined the Department of Pharmaceutical Sciences at Guru Nanak Dev University, Amritsar in 1997. Throughout his academic career, he has held several leadership positions, including serving as Head of the Department for more than eight years. He has also served as Dean Colleges and Dean Student Welfare at Guru Nanak Dev University, Amritsar.

He has led major research projects funded by prominent organizations including UGC, DST, CSIR, and AICTE. Additionally, he was selected by the Ministry of Health & Family Welfare, Government of India, for a national health research funding study.

Independence and Compliance Verification

Kwality Pharmaceuticals Limited has verified that Dr. Bedi is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The company confirmed that Dr. Bedi is not related to any existing Director of the company, ensuring his independence in board matters. The appointment has been communicated to BSE Limited under the company's scrip code 539997.